Buy or sell Tessera Therapeutics stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
Tessera Therapeutics Stock
Tessera Therapeutics is a biotechnology company that focuses on a new category of genetic medicines.
About Tessera Therapeutics Stock
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.
Indigo, Tessera Therapeutics, Codiak Biosciences, Rubius Therapeutics, Cygnal Therapeutics
One97, Flipkart, Delhivery, Cruise, OneWeb, Tokopedia, Ola, Rappi, Devoted Health, AUTO1 Group
Co-Founder & Chief Scientific Officer
President and CFO
Chief Data Officer
Co-Founder, Chief Executive Officer & Board member
Geoffrey von Maltzahn
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase